On Wednesday, November 6th, American Gene Technologies (AGT) submitted a document almost 1,000 pages in length to the FDA that outlines what they say could have the cure for HIV/AIDS. The research facility that is based in Maryland submitted their research for Phase I trial of its autologous cell therapy for HIV reports BioBuzz.
The company has been working to develop an innovative HIV treatment that could use immunotherapy to eliminate the possibility for AIDS progression and immunity from future HIV exposures, if successful.
This new possibility is unique because it would focus on immune cells necessary for creating strong immunity against a virus and by protecting these cells to disable HIV. If successful, the cell’s natural process of building immunity can be restored and future exposure to HIV will be countered by an individual’s own immune system.
CEO of AGT, Jeff Galvin, says:
We want to get these people out of jail and back to normal life. We see this as critically important we need to move these people from anti-retroviral control to permanent immunity and we think our project may be able to do that.
AGT expects to hear back from the FDA by the end of the year or early January with information on whether they can move forward with clinical trials or not.
Why is it that news from these scientific institutions is important?
In the early days of the HIV/AIDS crisis, the BioHealth Capital Region was the epicenter of HIV/AIDS research, with much of this groundbreaking research occurring within the lab of the now famed NIH researcher, Dr. Robert Gallo. In 1983 and 1984 Gallo and his collaborators co-discovered and confirmed that the virus responsible for the killer disease known as AIDS was human T lymphotropic virus type III (HTLV-III). Gallo and the company went on to develop the first test that identified the virus in humans—the HIV-antibody blood test.
The 1995 approval of Highly Active Antiretroviral Treatment (HAART), which was the result of the remarkable, collaborative efforts of the scientific community, led to the reduction of AIDS-related deaths and hospitalizations by 60-80%. A short time later what was once a three-drug cocktail had been transformed into a pill taken once daily by HIV sufferers. – biobuzz.io
Currently there are approximately 1.1 million people living with HIV/AIDS in the U.S. and over 19.5 million people world-wide estimated to be receiving antiretroviral treatment.